Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 28 August 2020.

Making headlines this time are setbacks in multiple clinical trials, plans for hyperimmune globulin in COVID-19 and a big divestment deal in Japan.

Stories mentioned in this edition:

(Also see "Third Death In Audentes’ XLMTM Gene Therapy Trial" - Scrip, 21 Aug, 2020.)

(Also see "Novartis Hits Spartalizumab Phase III Setback In Melanoma" - Scrip, 24 Aug, 2020.)

(Also see "Bristol/Agios AML Drug Idhifa Fails In Phase III" - Scrip, 25 Aug, 2020.)

(Also see "After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?" - Scrip, 24 Aug, 2020.)

(Also see "Takeda Confirms $2.3bn Deal With Blackstone For Japan Consumer Business" - Scrip, 24 Aug, 2020.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts